TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38797460
Drug: Phenoxymethyl Penicillin
Normalized name: Phenoxymethyl Penicillin
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenoxymethyl Penicillin (Pen V arm, twice daily oral penicillin)
Study: 38797460
Drug: Benzathine Benzyl
Normalized name: Benzathine benzylpenicillin
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Benzathine Benzyl Penicillin G (BPG arm, every-28-day intramuscular penicillin)
Study: 38797460
Drug: Benzathine Benzyl
Normalized name: Benzathine benzylpenicillin
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Benzathine Benzyl Penicillin G (BPG arm)
Study: 38797482
Drug: Lycopene-rich vegetable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lycopene-rich vegetable juice providing low (13.1 mg), medium (23.9 mg), and high (31.0 mg) daily total carotenoid doses for 8 weeks.
Study: 38797635
Drug: Cardiac index-guided
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac index-guided therapy (using intravenous fluids and dobutamine)
Study: 38797835
Drug: Low-carbohydrate and
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-carbohydrate and energy-restricted (LCER) diet (Pharm-TCR: <50 g carbohydrates; ~850-1100 kcal/day; n=20)
Study: 38797835
Drug: Treatment-as-usual (TAU;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual (TAU; n=16)
Study: 38798396
Drug: Novel non-invasive
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel non-invasive biomarkers of GERD, BE, airway hyperreactivity (AHR), treatment efficacy, and severity of symptoms.
Study: 39422912
Drug: Montelukast 10
Normalized name: montelukast 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 10 mg once daily for 14 days
Study: 38798539
Drug: Daily calorie
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily calorie restriction (CR)
Study: 38799274
Drug: Rimegepant 75
Normalized name: rimegepant 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimegepant 75 mg (up to once daily as needed for 52 weeks)
Study: 38799276
Drug: MEMS bottles
Normalized name: danicopan
DrugBank: Danicopan (DB15401)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEMS bottles containing opioid medication for a 90-day period
Study: 38799276
Drug: Standard medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medication bottles
Study: 38799438
Drug: CHM granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHM granules (9g/sachet, two times daily) for 7 days
Study: 38800061
Drug: internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: internet-based cognitive behavioral therapy for insomnia (iCBT-I) for 2 months
Study: 38800061
Drug: internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: internet-based cognitive behavioral therapy for insomnia (iCBT-I)
Study: 38800121
Drug: Polysaccharide hemostatic
Normalized name: collagen hemostat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polysaccharide hemostatic (PH) topical product
Study: 38800408
Drug: DPCP 0.04%
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPCP 0.04% ointment applied twice weekly to four in-transit metastases, concurrent with pembrolizumab 300 mg every three weeks.
Study: 38800408
Drug: DPCP 0.04%
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPCP 0.04% ointment
Study: 38800822
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg triamcinolone
Study: 38801606
Drug: Apremilast 30
Normalized name: apremilast 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apremilast 30 mg twice daily for 16 weeks plus existing topical therapy
Study: 38801641
Drug: Standardized Chinese
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized Chinese medicine (CM) treatment ≥3 months
Study: 38801641
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical treatment (non-CM cohort)
Study: 38801826
Drug: Ad26.RSV.preF-RSV preF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad26.RSV.preF-RSV preF protein (one intramuscular injection)
Study: 38802273
Drug: ECG patches
Normalized name: Ecgonine
DrugBank: Ecgonine (DB01525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECG patches and wearable bracelet
Study: 38802569
Drug: Human amniotic
Normalized name: Human Amniotic Fluid
DrugBank: Human Amniotic Fluid (DB15871)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human amniotic epithelial stem cells (hAESCs) injected on day -1 or day 7 post-PBMC infusion
Study: 38802634
Drug: Venglustat in
Normalized name: Venglustat
DrugBank: Venglustat (DB14966)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venglustat in combination with imiglucerase
Study: 38802866
Drug: CPM therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPM therapy (n=48)
Study: 38802866
Drug: CPM therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPM therapy
Study: 38802888
Drug: CFRT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CFRT with sequential boost (50 Gy in 25 fractions, sequential boost of 10 Gy in 5 fractions to the tumor bed)
Study: 38803220
Drug: Bortezomib-based chemotherapy
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib-based chemotherapy plus therapeutic plasmapheresis (TPP) with 4% human albumin solution
Study: 38803628
Drug: Liraglutide 3
Normalized name: liraglutide 3.6 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide 3 mg with a targeted prescribing pathway
Study: 38804514
Drug: Felzartamab (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felzartamab (16 mg/kg)
Study: 38804517
Drug: Plozasiran 10
Normalized name: Plozasiran
DrugBank: Plozasiran (DB18997)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plozasiran 10 mg (quarterly dose)
Study: 38804517
Drug: Plozasiran 25
Normalized name: Plozasiran
DrugBank: Plozasiran (DB18997)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plozasiran 25 mg (quarterly dose)
Study: 38804517
Drug: Plozasiran 50
Normalized name: Plozasiran
DrugBank: Plozasiran (DB18997)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plozasiran 50 mg (quarterly dose)
Study: 38804517
Drug: Plozasiran 50
Normalized name: Plozasiran
DrugBank: Plozasiran (DB18997)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plozasiran 50 mg (half-yearly dose)
Study: 38804782
Drug: CK0801 Treg
Normalized name: Col-Treg
DrugBank: Col-Treg (DB18451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CK0801 Treg cell therapy
Study: 38804790
Drug: Olgotrelvir 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olgotrelvir 600 mg twice daily for 5 days
Study: 38805199
Drug: Twice-daily meditation
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily meditation
Study: 38805199
Drug: Once-daily meditation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily meditation
Study: 38805216
Drug: Immediate-intensive atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-intensive atorvastatin (80 mg daily on days 1-21; 40 mg daily on days 22-90)
Study: 38805216
Drug: Delayed-intensive statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed-intensive statin (placebo for days 1-3, followed by atorvastatin 40 mg daily on days 4-21, and then atorvastatin 40 mg daily on days 22-90)
Study: 38805216
Drug: Immediate-intensive atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-intensive atorvastatin
Study: 38805228
Drug: Vaginal natural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal natural progesterone therapy
Study: 38805242
Drug: SHR-1703 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-1703 (20 mg)
Study: 38805242
Drug: SHR-1703 (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-1703 (75 mg)
Study: 38805242
Drug: SHR-1703 (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-1703 (150 mg)
Study: 38805242
Drug: SHR-1703 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-1703 (300 mg)
Study: 38805242
Drug: SHR-1703 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-1703 (400 mg)
Study: 38806045
Drug: Tetravalent dengue
Normalized name: dengue virus live antigen, CYD serotype 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetravalent dengue vaccine TAK-003 (high-dose formulation)
Study: 38806045
Drug: Tetravalent dengue
Normalized name: dengue virus live antigen, CYD serotype 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetravalent dengue vaccine TAK-003 (standard approved formulation)
Study: 38806430
Drug: Bronchoscopic thermal
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bronchoscopic thermal vapour ablation (BTVA) treatment with the InterVapor system together with standard medical management
Study: 38806430
Drug: BTVA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: BTVA treatment
Study: 38806504
Drug: NOX-A12 (200/400/600
Approvals — FDA: no, EMA: no, PMDA: no
Description: NOX-A12 (200/400/600 mg per week)
Study: 38806504
Drug: NOX-A12 (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: NOX-A12 (600 mg per week)
Study: 38806504
Drug: NOX-A12 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: NOX-A12 (various doses)
Study: 38806700
Drug: BI 1467335
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 1467335 10 mg once daily for 12 weeks
Study: 38806873
Drug: Midazolam injection
Normalized name: midazolam Injection
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam injection via needle-free auto-injector ZENEO (10 mg)
Study: 38806873
Drug: Conventional syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional syringe midazolam injection (10 mg)
Study: 38807116
Drug: VR-based simulation
Normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VR-based simulation training on geriatric oral health care (implemented twice at two weeks apart)
Study: 38807146
Drug: TG103 (15.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: TG103 (15.0 mg)
Study: 38807146
Drug: TG103 (22.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: TG103 (22.5 mg)
Study: 38807146
Drug: TG103 (30.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: TG103 (30.0 mg)
Study: 38807165
Drug: Interaction-focused music
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interaction-focused music therapy with cancer-affected children and their significant others (INMUT-KB)
Study: 38807165
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy only with the child (MUT-K)
Study: 38807183
Drug: Social memory
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Social memory task administered in presence-only context
Study: 38807183
Drug: Social memory
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Social memory task administered in observation context
Study: 38807948
Drug: Insertable cardiac
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insertable cardiac monitor (ICM) in addition to standard post-MI treatment
Study: 38807948
Drug: Standard post-MI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard post-MI treatment without ICM
Study: 38808319
Drug: Metformin hydrochloride
Normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin hydrochloride 1000mg extended release once daily for 24 weeks in addition to standard-of-care WHO MB multidrug therapy (MDT) during 48 weeks.
Study: 38808319
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 24 weeks in addition to standard-of-care WHO MB multidrug therapy (MDT) during 48 weeks.
Study: 38808361
Drug: SCG101 T-cell
Normalized name: CD4CAR T cells
DrugBank: Anti-CD4 CAR T-cell therapy (DB17281)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCG101 T-cell therapy
Study: 38808476
Drug: Oral semaglutide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral semaglutide (3 mg escalating to 14 mg)
Study: 38808490
Drug: Esketamine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esketamine (0.2 mg/kg infused intravenously over 40 minutes after childbirth)
Study: 38809174
Drug: Zodasiran 50
Normalized name: Zodasiran
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zodasiran 50 mg
Study: 38809174
Drug: Zodasiran 100
Normalized name: Zodasiran
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zodasiran 100 mg
Study: 38809174
Drug: Zodasiran 200
Normalized name: Zodasiran
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zodasiran 200 mg
Study: 38809849
Drug: Benfotiamine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benfotiamine (600 mg or 1200 mg)
Study: 38809849
Drug: Benfotiamine (selected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benfotiamine (selected dose from phase 2A)
Study: 38810172
Drug: Fetal antiseizure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fetal antiseizure medication (ASM) exposure
Study: 38810600
Drug: Eculizumab (weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eculizumab (weekly induction of 600 mg or 900 mg followed by maintenance doses of 300 to 1200 mg every two weeks for up to 26 weeks)
Study: 38810968
Drug: Modified NHL-BFM-95
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified NHL-BFM-95 protocol combined with anaplastic lymphoma kinase inhibitor
Study: 38810968
Drug: Anaplastic lymphoma
Normalized name: Anaplastic lymphoma kinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anaplastic lymphoma kinase inhibitor maintenance therapy
Study: 38811045
Drug: Inhaled treprostinil
Normalized name: treprostinil Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled treprostinil (iTRE) up to 12 breaths (72 µg) 4 times daily
Study: 38811502
Drug: Esophageal self-dilation
Normalized name: Cellspan Esophageal Implant
DrugBank: Cellspan Esophageal Implant (DB18688)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esophageal self-dilation therapy (ESDT)
Study: 38811554
Drug: Combination bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Combination bevacizumab (BVZ) therapy
Study: 38811871
Drug: MAXPOWER Biological
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAXPOWER Biological Antibacterial Liquid
Study: 38811911
Drug: Erector spinae
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erector spinae plane block (ESPB) with 2.5 mg/ml ropivacaine
Study: 38811998
Drug: SGLT2 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SGLT2 inhibitor based treatment (empagliflozin and linagliptin)
Study: 38811998
Drug: Non-SGLT2 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-SGLT2 inhibitor based treatment (metformin and insulin)
Study: 38812507
Drug: Vaccinated with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccinated with two doses of CoronaVac, 2 to 8 weeks post-infection
Study: 38812507
Drug: SARS-CoV-2 infection
Normalized name: SARS-CoV-2 Sclamp
DrugBank: SARS-CoV-2 Sclamp (DB15849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SARS-CoV-2 infection in the pediatric population vaccinated with an inactivated SARS-CoV-2 vaccine
Study: 38813112
Drug: Fexagratinib 80
Normalized name: FEDRATINIB
DrugBank: Fedratinib (DB12500)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fexagratinib 80 mg bd on a continuous schedule until disease progression or unacceptable toxicity
Study: 38813388
Drug: EDP1815 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDP1815 (1 capsule daily)
Study: 38813388
Drug: EDP1815 (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDP1815 (4 capsules daily)
Study: 38813388
Drug: EDP1815 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDP1815 (10 capsules daily)
Study: 38813446
Drug: Vosoritide (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vosoritide (15 μg/kg/day, daily subcutaneous injection)
Study: 38813444
Drug: Dietary supplement
Normalized name: dietary supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplement (blueberry juice and extract, tryptophan 2 g, tyrosine 10 g)
Study: 38813551
Drug: R21/Matrix-M™ vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: R21/Matrix-M™ vaccine at varied doses (10µgR21/50 µg Matrix-M™, 5µgR21/25µg Matrix-M™, 5µgR21/50µg Matrix-M™)
Study: 38813551
Drug: R21/Matrix-M™ vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: R21/Matrix-M™ vaccine
Study: 38813815
Drug: ML GSP
Approvals — FDA: no, EMA: no, PMDA: no
Description: ML GSP model based on clinical and CT image features
Study: 38813838
Drug: onabotulinumtoxinA (onabotA)
Normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: onabotulinumtoxinA (onabotA) treatment
Study: 38814000
Drug: Acute bronchodilation
Normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute bronchodilation treatment, specific details not available.
Study: 38814343
Drug: Pre-treatment serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment serum histidine concentration
Study: 38814343
Drug: Pre-treatment serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment serum glutamate concentration
Study: 38814343
Drug: Pre-treatment serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment serum phenylalanine concentration
Study: 38814343
Drug: Pre-treatment serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment serum tyrosine concentration
Study: 38814343
Drug: Pre-treatment serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment serum valine concentration
Study: 38815151
Drug: Olaparib, starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaparib, starting dose of 135 mg/m2/dose, administered twice daily for 28-day cycles.
Study: 38815173
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (24 IU) four times daily for 8 weeks
Study: 38815230
Drug: Ordering of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ordering of recommended medication by providers
Study: 38832837
Drug: Propofol infusions
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusions
Study: 38816482
Drug: Carbamazepine (CBZ)
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine (CBZ) 300 mg per day
Study: 38816482
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of EA and CBZ
Study: 38816821
Drug: Biological age
Normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological age determination by DNA methylation profile
Study: 38816821
Drug: Tyrosine kinase
Normalized name: Protein-tyrosine kinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tyrosine kinase inhibitors
Study: 38816826
Drug: Personalized, risk-adapted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized, risk-adapted therapy
Study: 38818887
Drug: Fezolinetant 30
Normalized name: Fezolinetant
DrugBank: Fezolinetant (DB15669)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fezolinetant 30 mg once daily for 52 weeks
Study: 38818888
Drug: Fezolinetant 30
Normalized name: Fezolinetant
DrugBank: Fezolinetant (DB15669)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fezolinetant 30 mg/day
Study: 38818934
Drug: Ongericimab 150
Normalized name: Ongericimab
DrugBank: Ongericimab (DB18949)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ongericimab 150 mg every 2 weeks
Study: 38818934
Drug: Ongericimab 300
Normalized name: Ongericimab
DrugBank: Ongericimab (DB18949)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ongericimab 300 mg every 4 weeks
Study: 38819395
Drug: Donidalorsen (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donidalorsen (80 mg subcutaneously every 4 weeks)
Study: 38819395
Drug: Donidalorsen (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donidalorsen (80 mg subcutaneously every 8 weeks)
Study: 38819408
Drug: IP nivolumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: IP nivolumab (0.5, 1, or 3 mg/kg)
Study: 38819658
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg sebetralstat
Study: 38819658
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg sebetralstat
Study: 38819917
Drug: Dietary supplement
Normalized name: dietary supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplement (PediaFlù) plus standard of care (SoC)
Study: 38820078
Drug: Asciminib (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asciminib (80 mg once daily)
Study: 38820246
Drug: Community-wide universal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-wide universal HIV testing with treatment following national guidelines and TB screening (Arm B)
Study: 38820422
Drug: Luspatercept (1.0-1.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luspatercept (1.0-1.75 mg/kg, 21-day cycles)
Study: 38820549
Drug: ivonescimab plus
Normalized name: Ivonescimab
DrugBank: Ivonescimab (DB18931)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ivonescimab plus chemotherapy
Study: 38820586
Drug: Internet-based Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based Cognitive Behavioral Therapy (ICBT) with text messaging adjunct
Study: 38820857
Drug: Methylphenidate (MP)
Normalized name: 6 MP
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MP) administered before exercise
Study: 38820857
Drug: No methylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: No methylphenidate (MP) administered (without MP)
Study: 38821545
Drug: 'My Bowels
Approvals — FDA: no, EMA: no, PMDA: no
Description: 'My Bowels on Track' smartphone application with weekly/biweekly electronic patient-reported outcomes (PROs) and alerting system.
Study: 38822300
Drug: Daily tenofovir
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for 48 weeks
Study: 38822324
Drug: Digital cognitive
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital cognitive stimulation using HappyNeuron PRESCO software App on tablets, with three 20-minute sessions (first supervised by a neuropsychologist).